Equity Overview
Price & Market Data
Price: $2.07
Daily Change: -$0.259 / 12.50%
Daily Range: $2.07 - $2.33
Market Cap: $244,212,304
Daily Volume: 395,202
Performance Metrics
1 Week: -16.40%
1 Month: 38.41%
3 Months: 33.12%
6 Months: 216.7%
1 Year: 104.9%
YTD: 200.2%
Company Details
Employees: 9
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.